Editas Medicine (EDIT) Tops Q4 EPS by 17c
Tweet
Share
E-mail
Get Alerts EDIT Hot Sheet
Join SI Premium – FREE
Editas Medicine (NASDAQ: EDIT) reported Q4 EPS of ($0.06), $0.17 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $24.74 million versus the consensus estimate of $8.02 million.
For earnings history and earnings-related data on Editas Medicine (EDIT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Infleqtion raises Q2 revenue to $13.5M after contract restatement
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- Compass Point Starts Gorilla Tech Group/ (GRRR) at Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
